^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    RHOJ (Ras Homolog Family Member J)

    i
    Other names: RHOJ, Ras Homolog Family Member J, TCL, RASL7B, ARHJ, Rho-Related GTP-Binding Protein RhoJ, Ras Homolog Gene Family, Member J, Ras-Like Protein Family Member 7B, Tc10-Like GTP-Binding Protein, RAS-Like, Family 7, Member B, FLJ14445, TC10-Like Rho GTPase, TC10B, RHOI
    Associations

    News

    Trials
    1m
    RHOJ-induced chemotherapy resistance through epithelial-mesenchymal transition in drug-tolerant persister cells of head and neck cancer. (PubMed, Transl Oncol)
    RHOJ plays a critical role in modulating immunosuppressive signaling in both tumor and endothelial cells. RHOJ promotes the function of tumor-associated endothelial cells and drives EMT through its interaction with the IPO9/EpCAM signaling pathway, thereby increasing cell survival and drug resistance. Additionally, RHOJ may limit immune cell infiltration into the tumor core and promote immune evasion by contributing to vascular abnormalities and impaired barrier function.
    Journal • IO biomarker
    |
    RHOJ (Ras Homolog Family Member J)
    5ms
    RHOJ enhances adhesion and proliferation capabilities and suppresses apoptosis of melanoma cells by activating the Rap1 signaling pathway. (PubMed, Transl Cancer Res)
    Moreover, we found that the Rap1 signaling pathway activator could reverse the reduction in cell viability, proliferation, and adhesion, as well as the increase in apoptosis induced by si-RHOJ. In conclusion, RHOJ promotes melanoma cell adhesion and proliferation while inhibiting apoptosis through the activation of the Rap1 signaling pathway, highlighting the potential clinical implications of targeting RHOJ in melanoma treatment.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • VCL (Vinculin) • RHOJ (Ras Homolog Family Member J)
    |
    KIT expression
    6ms
    RhoJ promotes the progression of clear cell renal cell carcinoma via the TNF-α/NF-κB axis. (PubMed, Transl Androl Urol)
    Finally, since there are no available drugs targeting RhoJ, the virtual screening was used to identify potential RhoJ inhibitors based on an FDA-approved drug library, which showed that ergotamine, irinotecan, ledipasvir, pazopanib, and avodart were potential RhoJ-targeting drugs. Taken together, our findings provide novel insights into the role of RhoJ and identify available potential drugs for controlling ccRCC.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • RHOJ (Ras Homolog Family Member J)
    |
    pazopanib • irinotecan
    1year
    Nuclear localization of BRCA1-associated protein 1 is important in suppressing hepatocellular carcinoma metastasis via CTCF and NRF1/OGT axis. (PubMed, Cell Death Dis)
    Intriguingly, OGT transcription was upregulated and was also under the control of CTCF and NRF1 in human HCC, acting as a negative regulator of BAP1. To summarize, this study uncovered the underlying mechanisms of the regulation of BAP1 and that loss of the nuclear localization of BAP1 protein contributed to enhanced cell migration in vitro and more aggressive tumor behavior in human HCCs.
    Journal • BRCA Biomarker
    |
    BAP1 (BRCA1 Associated Protein 1) • NRF1 (Nuclear Respiratory Factor 1) • OGT (O-linked N-acetylglucosamine (GlcNAc) transferase) • RHOJ (Ras Homolog Family Member J)
    over1year
    Key Genes Involved in the Beneficial Mechanism of Hyperbaric Oxygen for Glioblastoma and Predictive Indicators of Hyperbaric Oxygen Prolonging Survival in Glioblastoma Patients. (PubMed, Curr Med Sci)
    HBO is beneficial for glioblastoma. Glioblastoma patients with these predictive indicators may prolong survival with HBO therapy. These potential therapeutic targets especially COL1A1, ADAMTS1 and PTBP3 deserve further validation.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    NF1 (Neurofibromin 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • PD-1 (Programmed cell death 1) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • MDM4 (The mouse double minute 4) • CDK6 (Cyclin-dependent kinase 6) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CA9 (Carbonic anhydrase 9) • COL1A1 (Collagen Type I Alpha 1 Chain) • MMP9 (Matrix metallopeptidase 9) • PCNA (Proliferating cell nuclear antigen) • ADAMTS1 (ADAM Metallopeptidase With Thrombospondin Type 1 Motif 1) • CDC42 (Cell Division Cycle 42) • CDKN1B (Cyclin dependent kinase inhibitor 1B) • CXCR5 (C-X-C Motif Chemokine Receptor 5) • DDIT3 (DNA-damage-inducible transcript 3) • IGFBP3 (Insulin-like growth factor binding protein 3) • IGFBP5 (Insulin Like Growth Factor Binding Protein 5) • BAK1 (BCL2 Antagonist/Killer 1) • CDC25A (Cell Division Cycle 25A) • COL12A1 (Collagen Type XII Alpha 1 Chain) • COL8A1 (Collagen Type VIII Alpha 1 Chain) • EFEMP1 (EGF Containing Fibulin Extracellular Matrix Protein 1) • GNRP (Ras-Specific Guanine Nucleotide-Releasing Factor 1) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • MCM2 (Minichromosome maintenance complex component 2) • RHOJ (Ras Homolog Family Member J) • NLRP2 (NLR Family Pyrin Domain Containing 2)
    |
    TP53 expression • CXCL12 expression • CDK6 expression • CDKN1B expression • PCNA expression
    over1year
    Letrozole-Based Near-Infrared Dynamic Imaging Targeting Ductal-Vascular RhoJ From Pancreatic Intraepithelial Neoplasia to Pancreatic Ductal Adenocarcinoma. (PubMed, Adv Healthc Mater)
    In vivo, the probe effectively targeted neoangiogenesis and Pancreatic Intraepithelial Neoplasias (PanINs) in various PDAC models, including the orthotopic, ectopic, spontaneous, and tamoxifen-induced tumors. Furthermore, multiple LTZi-MHI148 administrations attenuated PanINs to PDAC progression, suggesting its potential as a therapeutic intervention. These findings underscore the translational potential of LTZi-MHI148 for the early detection and targeted therapy of PDAC, utilizing NIR-I/II imaging to monitor RhoJ overexpression in precancerous ductal neoplasia associated with neoangiogenesis.
    Journal
    |
    RHOJ (Ras Homolog Family Member J)
    |
    tamoxifen • letrozole
    over1year
    Subtyping of gastric cancer based on basement membrane genes that stratifies the prognosis, immune infiltration and therapeutic response. (PubMed, Discov Oncol)
    In conclusion, we defined a novel molecular classification of GC based on BM genes, developed a prognostic risk model, and elucidated the cell subpopulations involved in BM remodeling at the single-cell level. This study has deepened the understanding of the relationship between GC metastasis and BM alterations, achieved prognostic stratification, and guided therapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • RHOJ (Ras Homolog Family Member J)
    over2years
    RHOJ Induces Epithelial-to-Mesenchymal Transition by IL-6/STAT3 to Promote Invasion and Metastasis in Gastric Cancer. (PubMed, Int J Biol Sci)
    Finally, blocking the IL-6/STAT3 signaling overcame RHOJ-mediated GC cells' growth and migration. These results indicate that the upregulation of RHOJ contributes to EMT-subtype GC invasion and metastasis via IL-6/STAT3 signaling, and RHOJ is expected to become a promising biomarker and therapeutic target for EMT-subtype GC patients.
    Journal
    |
    TP53 (Tumor protein P53) • IL6 (Interleukin 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • RHOJ (Ras Homolog Family Member J)
    over2years
    Elucidating the Associated Biological Function and Clinical Significance of RHOJ Expression in Urothelial Carcinoma. (PubMed, Int J Mol Sci)
    Moreover, the GSEA and imsig results further suggest a potential mechanistic link between RHOJ expression and immune-related pathways. Considering the increasing emphasis on immunotherapeutic strategies in bladder cancer management, our findings on RHOJ's potential as a diagnostic biomarker and its association with immune response open new avenues for therapeutic interventions.
    Journal • IO biomarker
    |
    RHOJ (Ras Homolog Family Member J)
    over2years
    Comprehensive Analysis of Differential Gene Expression and Correlated Immune Infiltration in Bladder Cancer. (PubMed, Iran J Public Health)
    CDC20, SPARCL1 and TMOD1 are promising biomarkers of bladder cancer. In addition, CDC20, SPARCL1 and TMOD1 are involved in cancer immune infiltration, which provides new targets in immune therapy in bladder cancer.
    Journal
    |
    CDC20 (Cell Division Cycle 20) • COL14A1 (Collagen Type XIV Alpha 1 Chain) • RHOJ (Ras Homolog Family Member J)
    almost3years
    Design, Synthesis, In Vitro and In Vivo Characterization of CDC42 GTPase Interaction Inhibitors for the Treatment of Cancer. (PubMed, J Med Chem)
    Recently, we reported the discovery of a novel lead compound, ARN22089, which blocks the interaction of CDC42 GTPases with specific downstream effectors...We discovered and optimized two novel inhibitors (27, ARN25062, and 28, ARN24928), which are optimal back-up/follow-up leads with favorable drug-like properties and in vivo efficacy in PDX tumors. These findings further demonstrate the potential of this class of CDC42/RHOJ inhibitors for cancer treatment, with lead candidates ready for advanced preclinical studies.
    Preclinical • Journal
    |
    BRAF (B-raf proto-oncogene) • CDC42 (Cell Division Cycle 42) • RHOJ (Ras Homolog Family Member J)
    |
    BRAF mutation
    |
    ARN22089